Antitumor activity via inhibition of glycosphingolipid biosynthesis

Area of Science:

• Biochemistry
• Cancer Biology
• Immunology

Background:

• Cancer cells produce glycolipids, potentially from host sources, influencing malignancy, tumor growth, immune evasion, and metastasis.
• Glucosylceramide (GlcCer) is a primary glycolipid precursor, synthesized from ceramide and uridine diphosphoglucose (UDP-glu).

Purpose of the Study:

• To investigate the therapeutic potential of inhibiting GlcCer synthesis in cancer treatment.
• To evaluate the impact of GlcCer and its inhibitor on cancer cell growth and host immunity.

Main Methods:

• Administering an inhibitor of GlcCer synthesis to mice with Ehrlich ascites tumor cells (EATC).
• Assessing tumor cure rates, survival times, and host immune response post-treatment.
• Evaluating the effect of GlcCer and the inhibitor on cancer cell proliferation in vivo.

Main Results:

• Complete cure in approximately 30% of tumor-bearing mice and significant life extension in the remainder.
• The majority of surviving mice developed immunity against subsequent EATC inoculation.
• Exogenous GlcCer enhanced cancer cell growth by about 50%, an effect largely reversed by the inhibitor.

Conclusions:

• Inhibiting GlcCer synthesis is a viable strategy for cancer chemotherapy.
• This approach can lead to tumor regression, host immunity, and has broad potential applications in cancer treatment.